Latest Breaking News On - Emophilia idogen se0014428561 - Page 1 : comparemela.com

Idogen has received the go-ahead from both the Swedish and Norwegian Medical Products Agencies to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in hemophilia A. The. | April 19, 2022

Norwegian medicalIdogen ab publ stock exchangePress releaseEmophilia idogen se0014428561